Featured conditions Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
Featured conditions
Displaying 3 studies
The purpose of this study is to establish the clinical performance of the Medfrontier Intact FGF23 immunoassay in patients with tumor induced osteomalacia (TIO) and X-linked hypophosphatemia (XLH).
This study aims to identify cases of FGF23-mediated oncogenic osteoomalacia in which the underlying phosphaturic mesenchymal has not been found and perform 68Ga-DOTATATE PET in these patients to localize the tumor.
The purpose of this study is to assess the effectiveness and safety of KRN23 administered to adult patients with inoperable tumor-induced osteomalacia or epidermal nevus syndrome.